This Article Full Text (PDF) Other Versions of this Article: AAC.01326-06v1 51/4/1563    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Nikonenko, B. V. Articles by Nacy, C. A. Search for Related Content PubMed PubMed Citation Articles by Nikonenko, B. V. Articles by Nacy, C. A.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.01326-06
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Drug therapy of experimental TB: improved outcome by combining SQ109, new diamine antibiotic, with existing TB drugs

Sequella, Inc., Rockville, Maryland, 20850, USA, and Central Research Institute for Tuberculosis, Moscow,107564, Russia

^* To whom correspondence should be addressed. Email: borisnikonenko{at}sequella.com.

	Abstract

Substitution of new diamine antibiotic SQ109 for Ethambutol (EMB) in a mouse model of chronic tuberculosis (TB) improved efficacy of combination drug therapy with first-line TB drugs Rifampin (RIF) and Isoniazid (INH), with or without Pyrazinamide (PZA): at 8 wk, lung bacteria were 1.5 log₁₀ lower in SQ109-containing regimens.